Below are the most recent publications written about "Anticholesteremic Agents" by people in Profiles.
-
Wong ND, Bang M, Block RC, Peterson ALH, Karalis DG. Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists). Am J Cardiol. 2021 08 01; 152:57-62.
-
Kelly MS, Sulaica EM, Beavers CJ. Role of Bempedoic Acid in Dyslipidemia Management. J Cardiovasc Pharmacol. 2020 10; 76(4):376-388.
-
de Ferranti SD, Shrader P, Linton MF, Knowles JW, Hudgins LC, Benuck I, Kindt I, O'Brien EC, Peterson AL, Ahmad ZS, Clauss S, Duell PB, Shapiro MD, Wilemon K, Gidding SS, Neal W. Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry. J Pediatr. 2021 02; 229:70-77.
-
Board C, Kelly MS, Shapiro MD, Dixon DL. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy. J Cardiovasc Pharmacol. 2020 05; 75(5):410-420.
-
Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Target Oncol. 2019 10; 14(5):527-539.
-
Piplani H, Marek-Iannucci S, Sin J, Hou J, Takahashi T, Sharma A, de Freitas Germano J, Waldron RT, Saadaeijahromi H, Song Y, Gulla A, Wu B, Lugea A, Andres AM, Gaisano HY, Gottlieb RA, Pandol SJ. Simvastatin induces autophagic flux to restore cerulein-impaired phagosome-lysosome fusion in acute pancreatitis. Biochim Biophys Acta Mol Basis Dis. 2019 11 01; 1865(11):165530.
-
Myers KD, Farboodi N, Mwamburi M, Howard W, Staszak D, Gidding S, Baum SJ, Wilemon K, Rader DJ. Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes. Circ Cardiovasc Qual Outcomes. 2019 08; 12(8):e005404.
-
Klein-Szanto AJP, Bassi DE. Keep recycling going: New approaches to reduce LDL-C. Biochem Pharmacol. 2019 06; 164:336-341.
-
Karalis DG, Mallya UG, Ghannam AF, Elassal J, Gupta R, Boklage SH. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia. Am J Cardiol. 2018 05 15; 121(10):1155-1161.
-
Sisson EM, Pamulapati L, Bucheit JD, Kelly MS, Dixon DL. Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. Pharmacotherapy. 2018 02; 38(2):164-171.